RuCorT-03: Induction and Consolidation Chemotherapy in Patients With Locally Advanced CRM-positive Rectal Cancer

• Sponsor: Blokhin's Russian Cancer Research Center (Other)
• Overall Status: Enrolling by invitation
• CT.gov ID: NCT04135313
• Collaborator: (none)
• Enrollment: 540
• Location: 1
• Arms: 2
• Anticipated Duration (Months): 59.4
• Patients Per Site Per Month: 9.1

Study Details

Study Description

Brief Summary

The purpose of this study is to determine whether the addition of 2 cycles of induction CapOx chemotherapy and 2 cycles of consolidation CapOx chemotherapy to standard chemoradiation improves 3-year disease-free survival in patients with locally advanced CRM"+" mid and low rectal cancer.

Condition or Disease	Intervention/Treatment	Phase
Rectal Neoplasms Malignant; Rectum Carcinoma; Rectal Cancer	Drug: Capecitabine; Drug: Oxaliplatin; Drug: Capecitabine; Radiation: Radiotherapy; Procedure: Rectal cancer surgery	Phase 3

Detailed Description

This trial aims to investigate the efficacy of adding neoadjuvant induction and consolidation chemotherapy compared to standard chemoradiotherapy in locally advanced rectal cancer patients with circumferential resection margin involvement. This is a prospective multicenter open-label randomized phase III clinical trial. Patients will be randomized using an online randomization system to receive either 2 cycles of induction CapOx (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 per os bid days 1-14) chemotherapy, followed by chemoradiotherapy (54 Gy in 2 Gy fractions with concomitant capecitabine 825 mg/m2 per os bid on radiation days), then 2 cycles of consolidation CapOx chemotherapy, surgery (10-12 weeks following chemoradiotherapy) and 2 cycles of adjuvant CapOx chemotherapy OR chemoradiotherapy (54 Gy in 2 Gy fractions with concomitant capecitabine 825 mg/m2 per os bid on radiation days), surgery (10-12 weeks following chemoradiotherapy) and 6 cycles of adjuvant CapOx chemotherapy. A stratification will be performed based on N stage, tumor location in the middle or low rectum and clinical center. Patients with middle or low rectal cancer without distant metastases, with involved circumferential resection margin (based on pretreatment MRI) will be included.

The target accrual is 270 patients in each treatment arm (including 10% potential data loss) based on potential benefit of 12% 3-yr disease-free survival (60% vs 72%), α=0,05, power 80% in the experimental arm. An interim analysis is planned after 50% of the patients will reach a 3-year followup. Pelvic Magnetic Resonance Imaging (MRI) is performed in all patients for staging before and after neoadjuvant chemotherapy and before surgery. Pelvic MRI is subject to central review. Conduction of this study and data collection are controlled by a local institutional board.

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 540 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Induction and Consolidation Chemotherapy in Locally Advanced Rectal Cancer Patients With Circumferential Resection Margin Involvement: a Multicenter Prospective Randomized Phase III Clinical Trial
• Actual Study Start Date: Oct 20, 2019
• Anticipated Primary Completion Date: Oct 1, 2024
• Anticipated Study Completion Date: Oct 1, 2024

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Neoadjuvant chemotherapy Patients receive 2 cycles of induction CapOx (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 per os bid days 1-14) chemotherapy, followed by chemoradiotherapy (54 Gy in 2 Gy fractions with concomitant capecitabine 825 mg/m2 per os bid on radiation days), then 2 cycles of consolidation CapOx chemotherapy, surgery (10-12 weeks following chemoradiotherapy) and 2 cycles of adjuvant CapOx chemotherapy	Drug: Capecitabine; 2000 mg/m2, bid, per os, days 1-14; Other Names: Xeloda ; Drug: Oxaliplatin; 130 mg/m2 iv day 1; Drug: Capecitabine; 825 mg/m2, bid, per os, only on days of radiation (Monday through Friday); Other Names: Xeloda ; Radiation: Radiotherapy; Pelvic radiotherapy dose: 44 Gy on regional nodes, 54 Gy on primary tumor in 2 Gy fractions; Procedure: Rectal cancer surgery; Laparoscopic or open total mesorectal excision or extralevator abdominoperineal resection
Active Comparator: Chemoradiotherpy Patients receive 54 Gy pelvic chemoradiotherapy in 2 Gy fractions with capecitabine 825 mg/m2 bid per os on radiation days and then surgery following 10-12 weeks. After surgery patients receive 6 cycles of adjuvant CapOx chemotherapy.	Drug: Capecitabine; 2000 mg/m2, bid, per os, days 1-14; Other Names: Xeloda ; Drug: Oxaliplatin; 130 mg/m2 iv day 1; Drug: Capecitabine; 825 mg/m2, bid, per os, only on days of radiation (Monday through Friday); Other Names: Xeloda ; Radiation: Radiotherapy; Pelvic radiotherapy dose: 44 Gy on regional nodes, 54 Gy on primary tumor in 2 Gy fractions; Procedure: Rectal cancer surgery; Laparoscopic or open total mesorectal excision or extralevator abdominoperineal resection

Outcome Measures

Primary Outcome Measures

1. 3-year disease-free survival [3 years]

Secondary Outcome Measures

1. Adjuvant chemotherapy compliance [6 months]

   Proportion of patients who receive a complete course of adjuvant chemotherapy

2. Acute chemotherapy toxicity [6 months]

   Toxicity measured according to NCI-CTCAE v.5.0

3. pathologic complete response rate (pCR) [1 month]

4. local recurrence rate [3 years]

5. 3-year overall survival [3 years]

6. Operative morbidity [30 days]

   Morbidity measured according to Clavien-Dindo classification

7. Preoperative tumor-associated complications rate [6 months]

   The rate of tumor-associated complications (bowel obstruction, bleeding etc) during neoadjuvant chemotherapy

8. Sphincter preservation rate [1 month]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 75 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Informed consent

• Histologically verified colon rectal adenocarcinoma 0-10 cm above the anal verge

• No distant metastases

• Circumferential resection margin (CRM) involvement (based on pelvic MRI)

• Eastern Cooperative Oncology Group (ECOG) status 0-2

• Haemoglobin (HGB) > 90 g/L

• Platelet Count (PLT) > 120x10*9/L

• Serum creatinine < 150 µmol/L

• Total bilirubin < 25 µmol/L

Exclusion Criteria:

• inability to obtain informed consent

• distant metastases

• cT2N0M0 rectal cancer

• synchronous or metachronous tumors

• previous chemotherapy or radiotherapy

• clinically significant cardiovascular disorders (myocardial infarction < 6 months before visit, stroke < < 6 months before visit, instable angina < 3 months before visit, arrhythmia, uncontrolled hypertension > 160/100 mm hg

• clinically significant neurological disorders

• previous neuropathy 2 or higher

• current infection or heavy systemic disease

• pregnancy, breastfeeding

• ulcerative colitis

• individual intolerance to treatment components

• proven dihydropyrimidine dehydrogenase (DPD) deficiency

• participation in other clinical trials

• psychiatric disorders, which render patient unable to follow instructions or understand his/her condition

• technical inability to perform pelvic MRI

• inability of long-term followup of the patient

• HIV

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	N.N.Blokhin Russian Cancer Research Center	Moscow		Russian Federation	115478

Sponsors and Collaborators

• Blokhin's Russian Cancer Research Center

Investigators

• Principal Investigator: Zaman Z Mamedli, PhD, N.N.Blokhin Russian Cancer Research Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Sergey Gordeyev, Principal Investigator, Consultant surgeon, Blokhin's Russian Cancer Research Center
• ClinicalTrials.gov Identifier: NCT04135313
• Other Study ID Numbers: RuCorT-03
• First Posted: Oct 22, 2019
• Last Update Posted: Feb 9, 2021
• Last Verified: Feb 1, 2021

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Sergey Gordeyev, Principal Investigator, Consultant surgeon, Blokhin's Russian Cancer Research Center: rectal cancer; induction chemotherapy; consolidation chemotherapy; neoadjuvant chemotherapy
• Additional relevant MeSH terms: Rectal Neoplasms; Neoplasms; Capecitabine; Oxaliplatin

Study Results

No Results Posted as of Feb 9, 2021